Biomarkers of Atrial Fibrillation: Which One Is a True Marker?

Overview

Journal Cardiol Res Pract

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2019 May 8

PMID 31061732

Citations 7

Authors

Pipin Ardhianto

Yoga Yuniadi

Affiliations

Soon will be listed here.

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmias and associated with the risk of stroke and death. Continuous development of the diagnostic tool and prognostic stratification may lead to optimal management of AF. The use of biomarkers in the management of AF has been grown as an interesting topic. However, the AF biomarkers are not yet well established in the major guidelines. Among these biomarkers, a lot of data show troponin and brain natriuretic peptides are promising for the prediction of future events. The troponin elevation in AF patients may not necessarily be diagnosed as myocardial infarction or significant coronary artery stenosis, and brain natriuretic peptide elevation may not necessarily confirm heart failure. Troponin T and troponin I may predict postoperative AF. Furthermore, troponin and brain natriuretic peptide gave better prognostic performance when compared with the risk score available today.

Citing Articles

Effect of an Intensive Lifestyle Intervention on Circulating Biomarkers of Atrial Fibrillation-Related Pathways among Adults with Metabolic Syndrome: Results from a Randomized Trial.

Li L, Alonso A, Romaguera D, Alonso-Gomez A, Razquin C, Tojal-Sierra L J Clin Med. 2024; 13(7).

PMID: 38610897 PMC: 11012583. DOI: 10.3390/jcm13072132.

Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial.

Schmalstieg-Bahr K, Gladstone D, Hummers E, Suerbaum J, Healey J, Zapf A Eur J Gen Pract. 2024; 30(1):2327367.

PMID: 38497412 PMC: 10949835. DOI: 10.1080/13814788.2024.2327367.

microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation.

Desantis V, Potenza M, Sgarra L, Nacci C, Scaringella A, Cicco S Int J Mol Sci. 2023; 24(6).

PMID: 36982382 PMC: 10049145. DOI: 10.3390/ijms24065307.

Prognostic Value of Troponin in Patients with Atrial Fibrillation Admitted to an Emergency Department: Review and Meta-Analysis.

Lucrecia Maria B, Marcelo T, Andreina G, Juan Pablo C J Atr Fibrillation. 2021; 13(3):2346.

PMID: 34950306 PMC: 8691335. DOI: 10.4022/jafib.2346.

Biomarkers Utility: At the Borderline between Cardiology and Neurology.

Ion A, Stafie C, Mitu O, Ciobanu C, Halitchi D, Costache A J Cardiovasc Dev Dis. 2021; 8(11).

PMID: 34821692 PMC: 8621331. DOI: 10.3390/jcdd8110139.

References

Pedersen O, BAGGER H, Kober L, Torp-Pedersen C . Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999; 100(4):376-80. DOI: 10.1161/01.cir.100.4.376. View

Maynard S, Menown I, Adgey A . Troponin T or troponin I as cardiac markers in ischaemic heart disease. Heart. 2000; 83(4):371-3. PMC: 1729379. DOI: 10.1136/heart.83.4.371. View

Goette A, Staack T, Rocken C, Arndt M, Geller J, Huth C . Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000; 35(6):1669-77. DOI: 10.1016/s0735-1097(00)00611-2. View

Silvet H, Young-Xu Y, Walleigh D, Ravid S . Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol. 2003; 92(9):1124-7. DOI: 10.1016/j.amjcard.2003.07.010. View

Tsai C, Lai L, Lin J, Chiang F, Hwang J, Ritchie M . Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004; 109(13):1640-6. DOI: 10.1161/01.CIR.0000124487.36586.26. View

Sharma S, Jackson P, Makan J . Cardiac troponins. J Clin Pathol. 2004; 57(10):1025-6. PMC: 1770452. DOI: 10.1136/jcp.2003.015420. View

Redfearn D, Ratib K, Marshall H, Griffith M . Supraventricular tachycardia promotes release of troponin I in patients with normal coronary arteries. Int J Cardiol. 2005; 102(3):521-2. DOI: 10.1016/j.ijcard.2004.05.076. View

Knudsen C, Omland T, Clopton P, Westheim A, Wu A, Duc P . Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005; 46(5):838-44. DOI: 10.1016/j.jacc.2005.05.057. View

Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E . Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006; 47(1):46-50. DOI: 10.1097/01.fjc.0000193808.99773.28. View

10.

Goetze J, Friis-Hansen L, Rehfeld J, Nilsson B, Svendsen J . Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006; 27(14):1648-50. DOI: 10.1093/eurheartj/ehl109. View

11.

Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X . Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006; 27(15):1841-6. DOI: 10.1093/eurheartj/ehl135. View

12.

Knayzer B, Abramov D, Natalia B, Tovbin D, Ganiel A, Katz A . Atrial fibrillation and plasma troponin I elevation after cardiac surgery: relation to inflammation-associated parameters. J Card Surg. 2007; 22(2):117-23. DOI: 10.1111/j.1540-8191.2006.00366.x. View

13.

Goette A, Lendeckel U . Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008; 10(2):238-41. DOI: 10.1093/europace/eum283. View

14.

Burstein B, Nattel S . Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008; 51(8):802-9. DOI: 10.1016/j.jacc.2007.09.064. View

15.

Breidthardt T, Noveanu M, Cayir S, Viglino M, Laule K, Hochholzer W . The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. Int J Cardiol. 2008; 136(2):193-9. DOI: 10.1016/j.ijcard.2008.04.045. View

16.

Wolf P, Abbott R, Kannel W . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8):983-8. DOI: 10.1161/01.str.22.8.983. View

17.

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I . Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372(9644):1174-83. DOI: 10.1016/S0140-6736(08)61242-8. View

18.

Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D . Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J. 2009; 30(11):1411-20. PMC: 2688683. DOI: 10.1093/eurheartj/ehp046. View

19.

Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View

20.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View